Trial Profile
Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms PREDICTOR
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
- 01 Feb 2022 Status changed from active, no longer recruiting to completed.
- 22 Mar 2021 Planned End Date changed from 1 Feb 2015 to 1 Dec 2021.